why choose us

🌐 Go to WebHealthNetwork.com
Go to Consumers Chat

Course: A Trifecta in the Management of Neurofibromatosis Type 1 Plexiform Neurofibromas: Patient Voices, Systemic Therapy, and Multidisciplinary Collaboration

CME Credits: 1.00

Released: 2025-03-31

Peripheral nerve sheath tumors or plexiform neurofibromas (PNs) occur in approximately 30%-50% of children and adults with neurofibromatosis type 1 (NF1). Treatment with MEK inhibitors achieved tumor volume reduction and symptom improvement in children and adults in clinical trials. To provide the best possible care for patients with NF1-PN, clinicians must be aware of the clinical data on MEK inhibitors and be able to select patients who will benefit from that treatment. Explore three educational modules and learn more about the rationale for MEK inhibitors and the efficacy of established and emerging therapies, adverse events, and optimizing collaboration among members of the multidisciplinary care team for diagnosis, treatment, symptom management, and monitoring of patients with this disease. Patient/caregiver interviews will also highlight the patient/caregiver experience and perspectives on diagnosis, treatment, and impact of NF1-PN on daily life.


View Full Course